专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120238460A1 RANTES LEVELS AS A DIAGNOSTIC AND THERAPEUTIC FOR ACUTE GRAFT VERSUS HOST DISEASE 审中-公开
标题翻译： RANTES水平作为诊断和治疗急性冠状动脉疾病
公开(公告)号：US20120238460A1
公开(公告)日：2012-09-20
申请号：US12739976
申请日：2008-11-10
申请人： Ofer Levy , Eva Guinan , Eugenie Suter
发明人： Ofer Levy , Eva Guinan , Eugenie Suter
IPC分类号： C40B30/04
CPC分类号： G01N33/6863 , G01N2333/523 , G01N2800/245 , G01N2800/50
摘要： Disclosed herein are methods for determining the likelihood of a subject to develop Acute graft versus host disease (aGVHD) upon receiving myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). One such method comprises assaying for baseline plasma concentration of RANTES in a sample obtained from the subject, and comparing the baseline plasma concentration of RANTES to a predetermined level. The method may further comprise assaying for day 7 plasma concentration of RANTES in sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for day 7 plasma concentration of RANTES in a sample obtained from the subject, and comparing the day 7 plasma concentration of RANTES to a predetermined level. Another such method comprises assaying for donor plasma concentration of RANTES in a sample obtained from a donor of the hemtopoietic stem cells, and comparing the donor plasma concentration of RANTES to a predetermined level, wherein a donor plasma concentration of RANTES less than the predetermined level indicates a likelihood of the subject to develop aGVHD upon receiving myeloablative allogeneic HSCT from that donor. Other methods include assaying for day 0, or for day 7, plasma concentration of MCP-1 in a sample obtained from the subject, and comparing the day 0 or day 7, plasma concentration of MCP-1 to a predetermined level.
摘要翻译：本文公开了用于确定受试者在接受清髓性同种异体造血干细胞移植（HSCT）时发展为急性移植物抗宿主病（aGVHD）的可能性的方法。一种这样的方法包括测定从受试者获得的样品中RANTES的基线血浆浓度，并将RANTES的基线血浆浓度与预定水平进行比较。该方法还可以包括测定从受试者获得的样品中RANTES的第7天血浆浓度，并将RANTES的第7天血浆浓度与预定水平进行比较。另一种这样的方法包括测定从受试者获得的样品中RANTES的第7天血浆浓度，并将RANTES的第7天血浆浓度与预定水平进行比较。另一种这样的方法包括测定从造血干细胞的供体获得的样品中RANTES的供体血浆浓度，并将RANTES的供体血浆浓度与预定水平进行比较，其中RANTES的供体血浆浓度小于预定水平表明接受来自该供体的清髓性同种异体HSCT的受试者可能发生GVHD。其他方法包括测定从受试者获得的样品中的第0天或第7天MCP-1的血浆浓度，并将MCP-1的血浆浓度与第0天或第7天的血浆浓度进行比较。

IPRDB

热门服务

关于我们

友情链接

联系方式